Chiasma Inc. (NASDAQ:CHMA) saw strong trading volume on Wednesday . 214,342 shares were traded during trading, an increase of 161% from the previous session’s volume of 81,988 shares.The stock last traded at $2.80 and had previously closed at $2.70.

Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Chiasma from a “hold” rating to a “sell” rating in a report on Tuesday, April 12th. William Blair downgraded Chiasma from an “outperform” rating to a “market perform” rating in a report on Monday, April 18th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $9.00 price objective (down from $43.00) on shares of Chiasma in a report on Monday, April 18th. Barclays PLC downgraded Chiasma from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $40.00 to $5.50 in a report on Monday, April 25th. Finally, Cowen and Company downgraded Chiasma from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $19.70.

The firm’s 50 day moving average price is $2.77 and its 200 day moving average price is $6.18. The stock’s market capitalization is $66.10 million.

Chiasma (NASDAQ:CHMA) last issued its earnings results on Wednesday, May 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. Analysts predict that Chiasma Inc. will post ($2.66) earnings per share for the current fiscal year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.